Research Paper Volume 12, Issue 2 pp 1577—1590
PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies
Figure 1. Circulating tumor DNA (ctDNA) gene mutation profiles for MBC patients who progressed after early-line therapy and had PIK3CA mutations in kinase domain (PIK3CA–KD, A) helix domain (PIK3CA–HD, B), other region (PIK3CA–OD, C) and other PI3K/AKT pathway aberrations (P/A, D).